Presented at 21st International AIDS Conference, 18th-22nd July, 2016 Durban, South Africa. Presented at 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17th-21st September, 2015 San Diego, CA.

Bioequivalence has been demonstrated.13 * BR - background regimen ** OBR - optimised background regimen 1. JAIDS 2014 66:393-8Ĥ KEY studies SINGLE FLAMINGO ARIA SPRING-2 SAILING STRIIVING VIKING-3ĪTRIPLA® SINGLE Treatment-naïve patients TRIUMEQ® † QD vs Atripla® QD (N=833) SUPERIOR EFFICACY vs Atripla® at weeks 48 (primary endpoint), 96 and 144 BOOSTED Pls FLAMINGO DTG + 2 NRTIs QD vs DRV/r + 2 NRTIs QD (N=484) vs darunavir/r at weeks 48 (primary endpoint) and 96 ARIA Treatment-naïve women TRIUMEQ QD vs ATV/r + TDF/FTC QD (N=495) vs atazanavir/r at week 48 (primary endpoint) INIs SPRING-2 DTG + 2 NRTIs QD vs RAL + 2 NRTIs BID (N=822) NON-INFERIOR EFFICACY vs raltegravir at weeks 48 (primary endpoint) and 96 SAILING Treatment-experienced, INI-naïve patients DTG QD + BR* vs RAL BID + BR* (N=719) Continuing ART STRIIVING stable-switch patients TRIUMEQ QD vs continuing ARV regimen (N=551) up to weeks 24 (primary endpoint) and 48 Heavily Treatment- Experienced VIKING-3 Heavily treatment experienced patients with RAL and/or EVG resistant HIV-1 DTG 50mg BD + OBR** (N=183)-single-arm study SUSTAINED EFFICACY † DTG 50mg + ABC 600mg/3TC 300mg were used. In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3TC 300 mg were used Bioequivalence was demonstrated between the TRIUMEQ as a single-pill and the separate co-administered tablet formulations of DTG + ABC/3TC TRIUMEQ Summary of Product Characteristics, January 2017 Weller S et al. The presenter should complete this slide, declaring any conflicts of interest he/she may have.ģ INTRODUCTION: TRIUMEQ AND DTG + ABC/3TC – BIOEQUIVALENCE DTG, dolutegravir ABC, abacavir 3TC, lamivudine UK/TRIM/0048/14(2) Date of preparation: March2017 Prescribing information is available at the end of this presentation *In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3TC 300 mg were used. Presentation on theme: 'TRIUmeq®* (DTG/ABC/3TC): Bioequivalence data'- Presentation transcript:ġ TRIUmeq®* (DTG/ABC/3TC): Bioequivalence data

Dtg accurip trial